The CD70-targeting CTX131 heads for the scrapheap.
ApexOnco Front Page
Recent articles
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
Thursday's unveiling of regular ASCO abstract yielded a few initial winners and losers.
Targeting GPC3 has scored a win for AstraZeneca’s Chinese partner, after Takeda drew a blank.
SEZ6 looks promising but early, while questions remain around toxicity with AbbVie's cMet ADCs.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Just-released abstracts leave investors hungry for details on BLU-222 and CB-010.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.